Bortecad

E852352
bortezomib-containing product branded formulation pharmaceutical drug

Bortecad is a branded pharmaceutical formulation of the proteasome inhibitor bortezomib, used primarily in the treatment of multiple myeloma and certain lymphomas.

Try in SPARQL Jump to: Statements Referenced by

Statements (35)

Predicate Object
instanceOf bortezomib-containing product ⓘ
branded formulation ⓘ
pharmaceutical drug ⓘ
belongsToRegimen bortezomib-based chemotherapy regimen ⓘ
contraindicatedIn severe hypersensitivity to bortezomib ⓘ
drugClass antineoplastic agent ⓘ
hasActiveIngredient bortezomib ⓘ
hasAdverseEffect anemia ⓘ
fatigue ⓘ
gastrointestinal disorders ⓘ
neutropenia ⓘ
peripheral neuropathy ⓘ
thrombocytopenia ⓘ
hasATCLevel3Class proteasome inhibitors ⓘ
hasDosageForm injectable ⓘ
powder for solution for injection ⓘ
hasMolecularTargetType protein complex ⓘ
hasPharmacologicalClass proteasome inhibitor ⓘ
indicatedForLineOfTherapy first-line treatment of multiple myeloma in combination regimens ⓘ
treatment of relapsed multiple myeloma ⓘ
isBrandOf bortezomib NERFINISHED ⓘ
mayBeUsedInCombinationWith dexamethasone NERFINISHED ⓘ
melphalan NERFINISHED ⓘ
prednisone ⓘ
mechanismOfAction reversible inhibition of 26S proteasome ⓘ
metabolism hepatic ⓘ
routeOfAdministration intravenous ⓘ
subcutaneous ⓘ
targets 26S proteasome ⓘ
proteasome beta 5 subunit ⓘ
therapeuticArea hematology ⓘ
oncology ⓘ
usedFor lymphoma ⓘ
mantle cell lymphoma ⓘ
multiple myeloma ⓘ

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

bortezomib → hasTradeName → Bortecad ⓘ